TISIDB

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform BIN1: Nucleus.; SUBCELLULAR LOCATION: Isoform IIA: Cytoplasm.
Domain	PF03114 BAR domain PF14604 Variant SH3 domain
Function	May be involved in regulation of synaptic vesicle endocytosis. May act as a tumor suppressor and inhibits malignant cell transformation.

> Gene Ontology [ TOP ]
Biological Process	GO:0006997 nucleus organization GO:0007050 cell cycle arrest GO:0010001 glial cell differentiation GO:0010720 positive regulation of cell development GO:0014013 regulation of gliogenesis GO:0014015 positive regulation of gliogenesis GO:0030100 regulation of endocytosis GO:0042063 gliogenesis GO:0042692 muscle cell differentiation GO:0045685 regulation of glial cell differentiation GO:0045687 positive regulation of glial cell differentiation GO:0045786 negative regulation of cell cycle GO:0048708 astrocyte differentiation GO:0048710 regulation of astrocyte differentiation GO:0048711 positive regulation of astrocyte differentiation GO:0050769 positive regulation of neurogenesis GO:0051640 organelle localization GO:0051647 nucleus localization GO:0051962 positive regulation of nervous system development GO:0060627 regulation of vesicle-mediated transport GO:0060988 lipid tube assembly GO:0065005 protein-lipid complex assembly GO:0071156 regulation of cell cycle arrest GO:0071825 protein-lipid complex subunit organization
Molecular Function	GO:0003779 actin binding GO:0048156 tau protein binding GO:0051015 actin filament binding GO:0070063 RNA polymerase binding
Cellular Component	GO:0005635 nuclear envelope GO:0015629 actin cytoskeleton GO:0030016 myofibril GO:0030017 sarcomere GO:0030018 Z disc GO:0030315 T-tubule GO:0030424 axon GO:0031674 I band GO:0032994 protein-lipid complex GO:0033267 axon part GO:0033268 node of Ranvier GO:0042383 sarcolemma GO:0043194 axon initial segment GO:0043292 contractile fiber GO:0044304 main axon GO:0044449 contractile fiber part GO:0060987 lipid tube

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04144 Endocytosis hsa04666 Fc gamma R-mediated phagocytosis
Reactome	R-HSA-8856828: Clathrin-mediated endocytosis R-HSA-199991: Membrane Trafficking R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between BIN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between BIN1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28714960	Non-small cell lung carcinoma	Promote immunity (infiltration and T cell function)	BIN1 is frequently attenuated or even silenced in human tumors including melanoma, breast, prostate, bladder and lung cancers. In the present study, we observed that there exists a negative correlation between the expression of PD-L1 and BIN1 in NSCLC tissues. The expression levels of BIN1 and PD-L1 were significantly related to the tumor, lymph node and metastasis grade (TNM) stage, invasion range and lymph node metastasis. Simultaneously, for NSCLC patients, the expression statuses of BIN1 and PD-L1 might be independent prognostic factors. Furthermore, the expression of tumor-infiltrating lymphocytes was positively associated with BIN1 expression and negatively related to PD-L1 expression in NSCLC tissues. Importantly, we showed that PD-L1 was under the control of BIN1. Bridging integrator-1 (BIN1) is a MYC-interacting adaptor protein that has features of a tumor suppressor. In addition, the overexpression of BIN1 could inhibit the c-MYC and epithelial growth factor receptor (EGFR)-dependent PD-L1 expression and reverse the suppressive immuno-microenvironment in vivo.

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of BIN1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of BIN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.661	0.12
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.631	0.722
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.698	0.651
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.151	0.764
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.024	0.991
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.372	0.89
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.053	0.885
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.146	0.906
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.022	0.988
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.52	0.744
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.357	0.877
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.303	0.0774

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of BIN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BIN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BIN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BIN1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BIN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of BIN1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between BIN1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	BIN1
Name	bridging integrator 1
Aliases	SH3P9; AMPH2; amphiphysin II; AMPHL; amphiphysin-like protein; box dependant MYC interacting protein 1; box- ......
Chromosomal Location	2q14
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting BIN1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse BIN1